Albert Bourla, Pfizer CEO (AP Images)

Pfiz­er/BioN­Tech makes sur­prise choice in fi­nal dash to Oc­to­ber fin­ish line for Covid-19 vac­cine

Pfiz­er and BioN­Tech have ze­roed in on an mR­NA vac­cine can­di­date to take in­to a piv­otal study — and it’s not the one that got an­a­lysts and in­vestors ex­cit­ed from a re­cent re­lease of da­ta.

On the same day Mod­er­na be­gan the US’ first Phase III Covid-19 vac­cine study, the part­ners an­nounced late in the evening that they have start­ed their own ri­val ef­fort with BNT162b2. A two-dose reg­i­men at a 30 µg dose will be test­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.